RESEARCH TRIANGLE PARK, N.C., June 12, 2024 (GLOBE NEWSWIRE) -- Science 37 Holdings, Inc., a leader in enhancing patient access to clinical trials, announced the final enrollment figures from its 20-month engagement with a clinical-stage drug development company advancing novel small molecule therapeutics for systemic neuro-immune disorders. Science 37 augmented the recruitment and enrollment activities taking place at study sites nationwide for this ongoing Phase 2 trial evaluating the effects of EP547 in ...